IL6 and COVID-19: Lastly, since this study represents patients admitted during the earlier phases of COVID-19, treatment strategies did not include remdesivir, interleukin 6 (IL-6) antagonists, convalescent plasma, or dexamethasone, which are now commonly utilized [23].